^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

BRCA2 expression

i
Other names: BRCA2, BRCC2, FACD, FAD, FAD1, FANCD, FANCD1, Breast cancer 2, early onset
Entrez ID:
4d
DISRUPTION OF POLYUNSATURATED FATTY ACID BIOSYNTHESIS DRIVES STING-DEPENDENT ACUTE MYELOID LEUKEMIA CELL MATURATION AND DEATH. (PubMed, J Biol Chem)
Similarly, STING agonism attenuated PD-AML survival, however, STING activation also reduced healthy granulocyte numbers. Collectively, these data unveil a previously unrecognized importance of PUFA biosynthesis in leukemogenesis and that imbalances in PUFA metabolism can drive STING-mediated AML maturation and death.
Journal
|
STING (stimulator of interferon response cGAMP interactor 1)
|
BRCA2 expression
19d
Meteorin-like (METRNL) attenuates hypertensive induced cardiac hypertrophy by inhibiting autophagy via activating BRCA2. (PubMed, Biochim Biophys Acta Mol Basis Dis)
But when BRCA2 expression is knocked down, this effect will be suppressed. Collectively, METRNL emerges as a potential therapeutic target for hypertensive cardiomyopathy.
Journal • BRCA Biomarker
|
BRCA2 (Breast cancer 2, early onset)
|
BRCA2 expression
2ms
Brain tissue- and cell type-specific eQTL Mendelian randomization reveals efficacy of FADS1 and FADS2 on cognitive function. (PubMed, Transl Psychiatry)
This study revealed putative causal effect of FADS1/FADS2 expression in brain tissues and blood on cognitive function. These findings provided evidence to prioritize FADS gene as potential target gene for maintenance of cognitive function.
Journal
|
FADS2 (Fatty Acid Desaturase 2)
|
BRCA2 expression
2ms
The effect of human umbilical cord mesenchymal stem cells conditioned medium combined with tamoxifen drug on BRCA1 and BRCA2 expression in breast cancer mouse models. (PubMed, Mol Biol Rep)
Our findings evidenced that UCMSCs-CM could be considered as a potential therapeutic option to modulate Tamoxifen chemosensitivity by regulating BRCA1 in breast cancer.
Preclinical • Journal • BRCA Biomarker
|
ER (Estrogen receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
|
BRCA1 expression • BRCA2 expression
|
tamoxifen
2ms
mRNA Expression and Methylation of the RAD51, ATM, ATR, BRCA1, and BRCA2 Genes in Gastric Adenocarcinoma. (PubMed, Biomark Insights)
Our results suggest RAD51, BRCA1, and BRCA2 methylation as a frequent epigenetic mechanism in gastric cancer, support the hypothesis that reduced BRCA1 expression participates in disease progression, and show an association between RAD51 mRNA and perineural invasion and mortality that may be considered unexpected, considering the former immunohistochemical studies. The lack of correlation between immunohistochemistry and mRNA, and even the inverse association, for ATR, can be seen as indicative of action of post-transcriptional or post-translational regulatory mechanisms, to be better investigated.
Journal • BRCA Biomarker
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • RAD51 (RAD51 Homolog A)
|
BRCA1 expression • ATM expression • BRCA2 expression
2ms
Mismatch repair protein MLH1 suppresses replicative stress in BRCA2 deficient breast tumors. (PubMed, J Clin Invest)
Furthermore, we described that estrogen induces MLH1 expression through estrogen receptor alpha (ERα), which might explain why the majority of BRCA2 mutation carriers develop ER positive breast cancer. Taken together, our findings reveal a role of MLH1 in relieving replicative stress and how it may contribute to the establishment of BRCA2-deficient breast tumors.
Journal • Mismatch repair • BRCA Biomarker
|
ER (Estrogen receptor) • BRCA2 (Breast cancer 2, early onset) • MLH1 (MutL homolog 1) • FEN1 (Flap Structure-Specific Endonuclease 1) • DNA2 (DNA Replication Helicase/Nuclease 2)
|
BRCA2 mutation • ER positive • ER expression • BRCA2 overexpression • BRCA2 expression
3ms
Expression and Localization of Ferritin-Heavy Chain Predicts Recurrence for Breast Cancer Patients with a BRCA1/2 Mutation. (PubMed, Cancers (Basel))
Moreover, we did not detect an association between FTH1 expression and the amount of CD45+ (p = 0.13), CD8+ (p = 0.18), CD4+ (p = 0.20) or FOXP3+ cells (p = 0.17). Consequently, the mechanism underlying the worse recurrence-free survival of nFTH1 expression in BRCA1/2 mutation carriers needs further investigation.
Journal • BRCA Biomarker
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • CD8 (cluster of differentiation 8) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • FOXP3 (Forkhead Box P3) • FTH1 (Ferritin Heavy Chain 1)
|
BRCA2 mutation • BRCA1 mutation • BRCA1 expression • BRCA2 expression • FOXP3 expression
3ms
Targeted inhibition of the ATR/CHK1 pathway overcomes resistance to olaparib and dysregulates DNA damage response protein expression in BRCA2 ovarian cancer cells. (PubMed, Sci Rep)
Antitumor activity of olaparib alone or combined with an ATR inhibitor (ATRi, ceralasertib) or CHK1 inhibitor (CHK1i, MK-8776) was evaluated in OC cell lines sensitive (PEO1, PEO4) and resistant (PEO1-OR) to olaparib. Overall, the addition of ATRi or CHK1i to olaparib effectively overcomes resistance to PARPi exerting anti-proliferative effect in BRCA2 olaparib-resistant OC cells and alters expression of DDR-related proteins. These new molecular insights into cellular response to olaparib combined with ATR/CHK1 inhibitors might help improve targeted therapies for olaparib-resistant OC.
Journal • BRCA Biomarker • PARP Biomarker
|
ABL1 (ABL proto-oncogene 1) • BRCA2 (Breast cancer 2, early onset) • CASP3 (Caspase 3) • CASP7 (Caspase 7) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
BRCA2 expression
|
Lynparza (olaparib) • ceralasertib (AZD6738) • MK-8776
4ms
Epigenetically Downregulated Breast Cancer Gene 2 through Acetyltransferase Lysine Acetyltransferase 2B Increases the Sensitivity of Colorectal Cancer to Olaparib. (PubMed, Cancers (Basel))
Low endogenous KAT2B expression, which we identify in a subset of cultured BRCA2-expressing CRC cells, leads to an accumulation of γH2AX (more DNA damage), resulting in low PARPi resistance in BRCA-expressing cells. Our results reveal KAT2B and histone acetylation as regulators of BRCA2 expression and PARPi responses in BRCA2-expressing CRC cells, providing further insights into molecular prerequisites for targeting BRCA-functional tumors.
Journal • BRCA Biomarker • PARP Biomarker
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
|
BRCA2 mutation • BRCA1 mutation • BRCA wild-type • BRCA mutation • BRCA2 expression
|
Lynparza (olaparib)
4ms
Globally shared TCR repertoires within the tumor-infiltrating lymphocytes of patients with metastatic gynecologic cancer. (PubMed, Sci Rep)
Immunotherapy, while not yet a mainstream treatment for gynecologic cancers, is advancing, with Dostarlimab recently receiving approval as a treatment for endometrial cancer...To explore the relationship between distant tissue biopsy regions and blood circulation, we investigated the TCR beta chain (TCRβ) in bulk tumor and matched blood samples from 39 patients with gynecologic cancer. We found that the TCR clones of TILs at different tumor sites were globally shared within patients and had high overlap with the TCR clones in peripheral blood.
Journal • Tumor-infiltrating lymphocyte • BRCA Biomarker • PD(L)-1 Biomarker • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • TRB (T Cell Receptor Beta Locus)
|
BRCA1 expression • BRCA2 expression
|
Jemperli (dostarlimab-gxly)
4ms
Sequencing-based functional assays for classification of BRCA2 variants in mouse ESCs. (PubMed, Cell Rep Methods)
We use this approach for functional evaluation of 223 variants listed in ClinVar. Our functional classification of BRCA2 variants is concordant with the classification reported in ClinVar or those reported by other orthogonal assays.
Preclinical • Journal • BRCA Biomarker
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
|
BRCA2 expression
4ms
Detection of clinically important BRCA gene mutations in ovarian cancer patients using next generation sequencing analysis. (PubMed, Am J Cancer Res)
Bisulfite-seq revealed a significant hypomethylation within promoter regions of mutated BRCA1 and BRCA2 genes in ovarian cancer samples, compared to non-mutated cases with pathogenic mutations, indicating the role of epigenetics in expression dysregulation as well. By uncovering clinically significant pathogenic mutations in BRCA1/2 genes and establishing their link with up-regulated gene expression, this study significantly advances our understanding of ovarian cancer's underlying causes in the Pakistani population.
Journal • Next-generation sequencing • BRCA Biomarker
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
|
BRCA2 mutation • BRCA1 mutation • BRCA1 expression • BRCA mutation • BRCA2 expression
5ms
Expression of human BRCA2 in Saccharomyces cerevisiae complements the loss of RAD52 in double-strand break repair. (PubMed, Curr Genet)
In addition, our results show that homology length influences repair efficiency in rad52 mutant cells, which impacts BRCA2 mediated repair of DSBs. This study provides evidence that S. cerevisiae could be used to monitor BRCA2 function, which can help in understanding the genetic consequences of BRCA2 variants and how they may contribute to cancer progression.
Journal • BRCA Biomarker
|
BRCA2 (Breast cancer 2, early onset) • RAD52 (RAD52 Homolog DNA Repair Protein)
|
BRCA wild-type • BRCA2 expression
5ms
Enhanced Cancer Cell Proliferation and Aggressive Phenotype Counterbalance in Breast Cancer with High BRCA1 Gene Expression (SABCS 2023)
Contrary to our initial hypothesis, we did not find any significant association between BRCA1 gene expression and survival outcomes in breast cancer patients. Based on the results of our study, we speculate that the interplay between enhanced cancer cell proliferation and aggressive tumor characteristics may counterbalance the effect of high BRCA1 expression in breast cancer.
BRCA Biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • CD8 (cluster of differentiation 8) • TGFB1 (Transforming Growth Factor Beta 1)
|
BRCA1 mutation • HER-2 negative • HRD • HRD + BRCA1 mutation • BRCA1 expression • BRCA2 expression
5ms
Role of the DNA Repair Machinery in Childhood B-Lineage Acute Lymphoblastic Leukemia: Aberrations of NBS1, Fancd2, Palb2 Genes and Expression of BRCA1 and BRCA2 (ASH 2023)
Finally, high expression of BRCA1 and BRCA2 genes in the host cells, at remission, is strongly correlated with a higher risk of relapse. Although this study has been performed with an adequate number of children with B-ALL, it is mandatory to perform a prospective project with a larger population.
Clinical • BRCA Biomarker
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PALB2 (Partner and localizer of BRCA2) • KMT2A (Lysine Methyltransferase 2A) • BRCA (Breast cancer early onset) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • FANCD2 (FA Complementation Group D2)
|
PALB2 mutation • MLL rearrangement • MLL rearrangement • BRCA1 expression • NBN mutation • BRCA2 expression
5ms
Loss of Function of SETD2 Tumor Suppressor in Chronic Myeloid Leukemia (CML) Progenitors Fosters Genomic Instability and Enhances Clonogenic Potential (ASH 2023)
Since SETD2 loss of function in CML is mediated by post-translation mechanisms, hence is reversible, therapeutic strategies aimed at interfering with these mechanisms may restore proliferation control and interrupt this cascade. Supported by AIRC IG 2019 (23001) and by Italian Ministry of Health, "Bando Ricerca Finalizzata 2016", project GR-2016-02364880.
BRCA Biomarker
|
ABL1 (ABL proto-oncogene 1) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • MSH6 (MutS homolog 6) • RAD51 (RAD51 Homolog A) • SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase) • CD34 (CD34 molecule) • AURKA (Aurora kinase A)
|
BRCA2 expression
5ms
Acetyl Transferase EP300 Deficiency Leads to Chronic Replication Stress in Adult T-Cell Leukemia/Lymphoma (ASH 2023)
However, EP300 deficient cells show a significant defect in innate immune system activation. Altogether these results suggest that mutations in EP300 cause chronic DNA replication stress, persistent genomic instability and innate immune system evasion underlie aggressive chemo-resistant tumorigenesis in humans.
Clinical • BRCA Biomarker
|
BRCA2 (Breast cancer 2, early onset) • EP300 (E1A binding protein p300) • MRE11A (MRE11 homolog, double strand break repair nuclease) • POLD3 (DNA Polymerase Delta 3)
|
EP300 mutation • BRCA2 expression
6ms
Immunohistochemical Detection of the Expressed BRCA1 and BRCA2 Proteins in Microenvironment of Malignant Breast Cancerous Tissues Infected with Human Mammary Tumor Virus. (PubMed, Asian Pac J Cancer Prev)
HMTV might contribute to the development of subsets of benign and malignant breast tumors. The observed rates of defective or mutated BRCA1 and BRCA2 genes in healthy tissues indicate a role in the development of breast tumors.
Journal • BRCA Biomarker
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
|
BRCA1 mutation • BRCA1 expression • BRCA2 expression
6ms
Vascular Supply Identification, Lesion Extension and Search for Tumor Similarity at a Distance by VTM in Breast Cancer (clinicaltrials.gov)
P=N/A, N=120, Not yet recruiting, Galzu Institute of Research, Teaching, Science and Applied Technology
New trial
|
TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • STK11 (Serine/threonine kinase 11) • S100P (S100 calcium binding protein P)
|
TP53 mutation • BRCA1 mutation • ATM mutation • PTEN mutation • TP53 expression • BRCA1 expression • ATM expression • BRCA2 expression
7ms
KMT2C expression and DNA homologous recombination repair factors in lung cancers with a high-grade fetal adenocarcinoma component. (PubMed, Transl Lung Cancer Res)
These results support the hypothesis that loss of KMT2C function decreases the expression of the HRR factors in H-FLACs. H-FLACs with low KMT2C expression may be a good indication for poly (ADP-ribose) polymerase (PARP) inhibitor-based therapy.
Journal • BRCA Biomarker • PARP Biomarker
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • KMT2C (Lysine Methyltransferase 2C) • ATR (Ataxia telangiectasia and Rad3-related protein)
|
KMT2C mutation • BRCA1 expression • ATM expression • BRCA2 expression • MLL3 mutation
8ms
The role of JARID1B in ovarian cancer (ESMO 2023)
This could also be underlined by the significant lower levels of JARID1B expression in cancers with high HRD scores. In order to further investigate the role of JARID1B in OC analyses on its interplay with CCL14 are ongoing.
BRCA Biomarker
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • ARID1B (AT-Rich Interaction Domain 1B) • KDM5B (Lysine Demethylase 5B)
|
BRCA2 mutation • BRCA1 mutation • HRD • BRCA wild-type • HRD + BRCA1 mutation • BRCA1 expression • BRCA2 expression • High HRD score
8ms
Selective Killing of BRCA2-Deficient Ovarian Cancer Cells via MRE11 Blockade. (PubMed, Int J Mol Sci)
In a clinical cohort of human ovarian tumours, low levels of BRCA2 expression with high levels of MRE11 co-expression were linked with worse progression-free survival (PFS) (p = 0.005) and overall survival (OS) (p = 0.001). We conclude that MRE11 is an attractive SL target, and the pharmaceutical development of MRE11 inhibitors for precision oncology therapeutics may be of clinical benefit.
Journal • BRCA Biomarker
|
BRCA2 (Breast cancer 2, early onset) • MRE11A (MRE11 homolog, double strand break repair nuclease) • TP53BP1 (Tumor Protein P53 Binding Protein 1)
|
BRCA2 expression
9ms
LCK facilitates DNA damage repair by stabilizing RAD51 and BRCA1 in the nucleus of chemoresistant ovarian cancer. (PubMed, J Ovarian Res)
Importantly, attenuation of LCK sensitizes HR-proficient eEOC cells to PARP inhibitor in cells and pre-clinical mouse studies. Collectively, our findings identify a novel therapeutic strategy to expand the utility of PARP targeted therapy in HR proficient ovarian cancer.
Journal • BRCA Biomarker • PARP Biomarker
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • RAD51 (RAD51 Homolog A) • LCK (LCK Proto-Oncogene, Src Family Tyrosine Kinase)
|
BRCA1 expression • BRCA2 expression • LCK overexpression
9ms
Mutations and expressions of breast cancer 1/2 in lung cancer. (PubMed, Thorac Cancer)
In general, our study better complements knowledge of the BRCA1/2 mutation status in the Chinese lung cancer patients, and firstly reveals the association between BRCA1/2 expression levels and prognosis of lung cancer patients, which may provide great value for the early diagnosis and clinical treatment of lung cancer.
Journal • BRCA Biomarker
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
|
BRCA2 mutation • BRCA1 mutation • BRCA1 expression • BRCA mutation • BRCA2 expression
10ms
Tumor-associated macrophages promote cisplatin resistance in ovarian cancer cells by enhancing WTAP-mediated N6-methyladenosine RNA methylation via the CXCL16/CXCR6 axis. (PubMed, Cancer Chemother Pharmacol)
Tumor-associated macrophages promote the cisplatin resistance of OC cells by enhancing WTAP-mediated N6-methyladenosine RNA methylation via the CXCL16/CXCR6 axis.
Journal • BRCA Biomarker • PARP Biomarker • IO biomarker
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BCL2 (B-cell CLL/lymphoma 2) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CXCR6 (C-X-C Motif Chemokine Receptor 6) • ALKBH5 (AlkB Homolog 5, RNA Demethylase) • CXCL16 (C-X-C Motif Chemokine Ligand 16) • WTAP (WT1 Associated Protein) • YTHDF1 (YTH N6-Methyladenosine RNA Binding Protein 1)
|
BCL2 expression • BRCA1 expression • BAX expression • BRCA2 expression
|
cisplatin
11ms
Low level of BRCA2 in peripheral blood lymphocytes is associated with an increased risk for head and neck squamous cell carcinoma (HNSCC) in a population of North-East India: a case-control study. (PubMed, Ecancermedicalscience)
Similarly, low levels of BRCA2 appeared to indicate a moderate, but non-significant risk for HNSCC in non-smokers aged between 36 and 56 years (OR = 1.15, 95% CI = 0.21-6.37). Low level of BRCA2 protein in the peripheral blood indicates increased risk for HNSCC.
Journal • BRCA Biomarker
|
BRCA2 (Breast cancer 2, early onset) • APEX1 (Apurinic/Apyrimidinic Endodeoxyribonuclease 1)
|
BRCA2 expression
1year
Expression- and splicing-based multi-tissue transcriptome-wide association studies identified multiple genes for estrogen receptor-negative breast cancer (AACR 2023)
Using a weighted ACAT method, in which breast tissue was given a 5-fold higher weight, we obtained similar results. In summary, our joint, multi-tissue TWAS corroborated previous GWAS loci for both ER- and overall breast cancer while highlighting how incorporating TWAS signals from multiple tissues and alternative splicing allowed us to discover new susceptibility genes for ER- breast cancer.
BRCA Biomarker
|
ER (Estrogen receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
|
BRCA1 mutation • ER negative • BRCA2 expression
1year
Application of AZD2281 combine with radiation therapy in glioblastoma (AACR 2023)
The current GBM treatment strategy is chemotherapy drug temozolomide (TMZ) combined with radiotherapy (RT), which has limited treatment effect, poor prognosis, high recurrence rate, and short prognosis survival time. In our animal data, we proved that combination therapy can effective suppression tumor growth and apoptosis-related protein signaling increased in DNA damage by IHC (p-ATM/p-CHK2/Caspase-3/Caspase-8/Caspase-9). In conclude, we suggested that AZD2281 can be used as a radiosensitizer to sensitize GBM patient to RT, which is dependent to BRCA1 expression.
BRCA Biomarker • PARP Biomarker
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset) • CHEK2 (Checkpoint kinase 2) • CASP3 (Caspase 3) • CASP8 (Caspase 8) • CASP9 (Caspase 9)
|
BRCA2 mutation • BRCA1 mutation • BRCA1 expression • BRCA mutation • BRCA2 expression
|
Lynparza (olaparib) • temozolomide
1year
Genomic and transcriptomic analyses identify distinct features of triple-negative inflammatory breast cancer (AACR 2023)
Patients were treated with neoadjuvant chemotherapy (NAC) or the anti-EGFR antibody panitumumab (PmAb) plus NAC (PmAb/NAC)... Our study demonstrated distinct genetic abnormalities, immune responses, and molecular characteristics associated with TN-IBC as well as differences related to patients’ responses to NAC and PmAb/NAC. This first comprehensive genomic, transcriptomic, and immune profiling of the largest TN-IBC patient cohort improves our understanding of the molecular landscape of the most aggressive subtype of breast cancer. Our analysis could lead to the discovery of novel prognostic biomarkers and druggable targets for TN-IBC.
Tumor mutational burden • BRCA Biomarker
|
TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • RB1 (RB Transcriptional Corepressor 1) • KEAP1 (Kelch Like ECH Associated Protein 1) • CD8 (cluster of differentiation 8) • PALB2 (Partner and localizer of BRCA2) • LMNA (Lamin A/C) • DDR2 (Discoidin domain receptor 2) • CDKN1B (Cyclin dependent kinase inhibitor 1B) • GATA3 (GATA binding protein 3) • NDRG1 (N-Myc Downstream Regulated 1) • BCL9 (BCL9 Transcription Coactivator) • SERPINA9 (Serpin Family A Member 9)
|
KEAP1 mutation • BRCA1 expression • BRCA2 expression
|
Vectibix (panitumumab)
1year
The expression and mutation of BRCA1/2 genes in ovarian cancer: a global systematic study. (PubMed, Expert Rev Mol Diagn)
There is no sufficient study available to conclude a systematic analysis for the expression of BRCA1/2 gene in OC. Research will continue to develop more diagnostic techniques based on the expression and mutation of BCRA1/2 genes for OC in the near future.
Review • BRCA Biomarker
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
|
BRCA2 mutation • BRCA1 mutation • BRCA1 expression • BRCA2 expression
1year
Prognostic And Predictive Value of Tumoral DNA Damage Repair Protein Expression in Patients with Resected Pancreatic Cancer. (PubMed, Clin Res Hepatol Gastroenterol)
Contrary to BRCA2, ATM, and P53, BRCA1 expression may be beneficial for prognosis in resected pancreatic cancer, while no predictive role was observed in terms of adjuvant platinum efficacy.
Retrospective data • Journal • BRCA Biomarker
|
TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
|
TP53 expression • BRCA1 expression • ATM expression • BRCA2 expression
|
cisplatin • gemcitabine
1year
CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer. (PubMed, Nat Commun)
Combined PARP and ATR inhibition overcomes PARP inhibitor resistance caused by CHEK2 loss. Our findings may inform the use of PARP inhibitors beyond BRCA1/2-deficient tumors and support reevaluation of current biomarkers for PARP inhibition in prostate cancer.
Journal • BRCA Biomarker • PARP Biomarker
|
TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • CHEK2 (Checkpoint kinase 2) • RAD51 (RAD51 Homolog A) • E2F7 (E2F Transcription Factor 7)
|
BRCA2 mutation • BRCA1 mutation • TP53 expression • BRCA2 expression
1year
Trial completion • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
|
BRCA2 mutation • BRCA1 mutation • HER-2 negative • BRCA1 mutation + BRCA2 mutation • BRCA1 expression • BRCA mutation • PGR expression • BRCA1 promoter methylation • BRCA2 expression
|
Lynparza (olaparib)
1year
Clinical and molecular features of ATM and BRCA2 mutations in metastatic prostate cancer. (ASCO-GU 2023)
ATM or BRCA2 mutations also predicted worse response to the AR-targeted abiraterone/enzalutamide therapies (HR 0.4, 0.3; CI 0.244-1.003, 0.172 – 0.6; P = 0.047, p < 0.001). We found that somatic ATM and BRCA2 mutations associated with differential OS outcomes, which may help tailor treatment decisions. At the molecular level, ATM- and BRCA2-mutated tumors exhibited differences in the landscape of co-occurring genomic and transcriptional features. These features unique to ATM or BRCA2 mutations can inform rationale for divergent treatment strategies and should be investigated.
Clinical • Tumor mutational burden • PD(L)-1 Biomarker • PARP Biomarker • BRCA Biomarker • IO biomarker • Metastases
|
TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability) • ATM (ATM serine/threonine kinase) • HRD (Homologous Recombination Deficiency) • RB1 (RB Transcriptional Corepressor 1) • PD-1 (Programmed cell death 1) • CCND1 (Cyclin D1) • ALDH1A3 (Aldehyde Dehydrogenase 1 Family Member A3) • HES4 (Hes Family BHLH Transcription Factor 4)
|
TP53 mutation • BRCA2 mutation • TMB-H • ATM mutation • PD-L1 amplification • BRCA2 expression
|
MI Tumor Seek™
|
enzalutamide capsule • abiraterone acetate
over1year
Gastric Cancer Risk and Pathogenesis in BRCA1 and BRCA2 Carriers. (PubMed, Cancers (Basel))
Given the strength of data published to date, a risk management strategy for GC among BRCA1/2 PV carriers is needed, and herein we also propose a potential strategy for GC risk management in this population. Moving forward, further study is clearly warranted to define the mechanistic relationship between BRCA1/2 PVs and development of GC as well as to determine how GC risk management should be factored into the clinical care of BRCA1/2 carriers.
Review • Journal • BRCA Biomarker
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
|
BRCA2 mutation • BRCA1 mutation • BRCA1 expression • BRCA2 expression
over1year
Analysis of matched primary and recurrent BRCA1/2 mutation-associated tumors identifies recurrence-specific drivers. (PubMed, Nat Commun)
Loss of heterozygosity (LOH) status is discordant in 25% of patient's primary and recurrent tumors, with switching between both LOH and lack of LOH found. Our study reveals multiple potential drivers of recurrent disease in BRCA1/2 mutation-associated cancer, improving our understanding of tumor evolution and suggesting potential biomarkers.
Journal • BRCA Biomarker • PARP Biomarker
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PARP1 (Poly(ADP-Ribose) Polymerase 1)
|
BRCA2 mutation • BRCA1 mutation • BRCA mutation • BRCA2 expression
over1year
Investigating the Role of Breast Cancer Susceptibility Gene 2 in High Glucose‐Induced Endothelial Dysfunction (AHA 2022)
Collectively, these findings reveal a novel role for BRCA2 as a regulator of endothelial function in context of HG treatment in vitro. Our RNA sequencing data shows theimportance of BRCA2 in regulating endothelial transcriptome and overall endothelial function. Further studies are underway; however, these results may provide important implications concerning the susceptibility of BRCA2 mutation carriers to HG-induced endothelial dysfunction as well as other CVDs.
BRCA Biomarker
|
BRCA2 (Breast cancer 2, early onset) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • NOS3 (Nitric oxide synthase 3)
|
BRCA2 mutation • TP53 expression • BRCA2 expression
over1year
Combined BRCA2 and MAGEC3 Expression Predict Outcome in Advanced Ovarian Cancers. (PubMed, Cancers (Basel))
Patients with optimal cytoreduction, loss of MAGEC3, and detectable BRCA2 expression had better overall (median OS: 127.9 vs. 65.3 months, p = 0.035) and progression-free (median PFS: 85.3 vs. 18.8 months, p = 0.002) survival compared to patients that were BRCA2 expressors with MAGEC3 normal levels. Our results suggest that combined expression of MAGEC3 and BRCA2 serves as a better predictor of prognosis than each marker alone.
Journal • BRCA Biomarker
|
BRCA2 (Breast cancer 2, early onset)
|
BRCA2 expression
over1year
Differential expression of DNA damage repair genes after chemoradiotherapy and inhibition rate in different bladder cancer cells. (PubMed, Transl Androl Urol)
The expression levels of RBBP8 and BRCA1 genes were associated with sensitivity to radiotherapy and chemotherapy in bladder cancer, and an increase in reactive expression after treatment led to worse sensitivity. Therefore, the reactive expression levels of BRCA1 and RBBP8 after chemoradiotherapy may be useful in evaluating the efficacy of olaparib combination therapy.
Journal • BRCA Biomarker • PARP Biomarker
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • RBBP8 (RB Binding Protein 8, Endonuclease)
|
BRCA1 expression • BRCA2 expression
|
Lynparza (olaparib)
over1year
Degradation of BRCA2 expression by hyperthermia sensitizes HRD-negative (BRCA2 wild-type) ovarian cancer cells to niraparib (ESMO Asia 2022)
The in vivo experiment showed that the treatment of Niraparib combined with HT slowed down the tumor growth rate and prolonged the survival of the mice bearing tumors. Conclusions Hyperthermia could enhance the sensitivity of BRCA2wt ovarian cancer to PARP inhibitors.
BRCA Biomarker • PARP Biomarker
|
BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset) • RAD51 (RAD51 Homolog A)
|
BRCA2 mutation • HRD • BRCA wild-type • BRCA mutation • BRCA2 expression
|
Zejula (niraparib)
over1year
MC180295 Inhibited Epstein-Barr Virus-Associated Gastric Carcinoma Cell Growth by Suppressing DNA Repair and the Cell Cycle. (PubMed, Int J Mol Sci)
LMP1 and BZLF1 are EBV genes with expression that is epigenetically regulated, and MC180295 could up-regulate their expression. In conclusion, MC180295 inhibited the growth of EBVaGC cells by suppressing DNA repair and the cell cycle.
Journal • BRCA Biomarker
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • TOP2A (DNA topoisomerase 2-alpha) • RAD51 (RAD51 Homolog A) • FANCM (FA Complementation Group M)
|
BRCA2 expression • TOP2A expression
over1year
Fatty acid desaturase 1 (FADS1) is a cancer marker for patient survival and a potential novel target for precision cancer treatment. (PubMed, Front Oncol)
Lastly, single nucleotide polymorphisms (SNPs) which are well-established expression quantitative trait loci (eQTLs) for FADS1 in normal human tissues are also significantly correlated with FADS1 expression in tumors of multiple tissue types, potentially serving as a marker to stratify cancer patients with high/low FADS1 expression in their tumor tissue. Our study suggests that FADS1 plays multiple roles in cancer biology and is potentially a novel target for precision cancer treatment.
Journal
|
TP53 (Tumor protein P53)
|
TP53 mutation • TP53 expression • BRCA2 expression • BRCA2 underexpression